{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/management/uncomplicated-infection/","result":{"pageContext":{"chapter":{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection","depth":2,"htmlHeader":"<!-- begin field 5c798f56-3632-433e-99b9-954c811c51e4 --><h2>Scenario: Uncomplicated infection</h2><!-- end field 5c798f56-3632-433e-99b9-954c811c51e4 -->","summary":"Covers the management of women presenting with an uncomplicated, isolated episode of vulvovaginal candidiasis.","htmlStringContent":"<!-- begin item 0f60c6bf-3e83-4fb9-8b4b-7bad6169a58f --><!-- begin field 0f3436a5-b6a7-448f-860a-acbc0156a9be --><p>From age 12 years onwards (Female).</p><!-- end field 0f3436a5-b6a7-448f-860a-acbc0156a9be --><!-- end item 0f60c6bf-3e83-4fb9-8b4b-7bad6169a58f -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"db874039-3251-5ba4-8c95-a4f3c1ad1978","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field fea8b7d5-c94f-421c-af07-906a734b5a97 --><h3>How should I manage uncomplicated vulvovaginal candidiasis?</h3><!-- end field fea8b7d5-c94f-421c-af07-906a734b5a97 -->","summary":null,"htmlStringContent":"<!-- begin item 0625f8ee-7270-4d6d-87aa-3d2657f18f82 --><!-- begin field 55741aef-3737-46d0-9633-372454882100 --><p><strong>To manage uncomplicated vulvovaginal candidiasis:</strong></p><ul><li><strong>Prescribe antifungal treatment.</strong><ul><li>The choice of treatment and formulation will depend on factors such as contraindications and cautions, the licenced age and indication for the product, and the person's preference.<ul><li><strong>For most women, </strong>prescribe an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#initial-courses-of-antifungals\">initial course</a> of an intravaginal antifungal cream or pessary (clotrimazole, econazole, miconazole, or fenticonazole) or an oral antifungal (fluconazole or itraconazole).</li><li><strong>For women aged 60 years and older,</strong> oral antifungals may be more acceptable than intravaginal antifungals because of the ease of administration.</li><li><strong>For girls </strong><strong>aged 12–15 years</strong><strong>,</strong> consider prescribing topical clotrimazole 1% or 2% applied 2–3 times a day, or seek specialist advice. Do not prescribe an intravaginal or oral antifungal.</li><li><strong>For breastfeeding women, </strong>prescribe an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#initial-courses-of-antifungals\">initial course</a> of intravaginal clotrimazole or miconazole, or oral fluconazole (if an intravaginal antifungal is unacceptable to the woman).</li></ul></li><li><strong>If there are vulval symptoms,</strong> consider prescribing a topical imidazole<em> </em>in addition to an oral or intravaginal antifungal. Options include:<ul><li>Clotrimazole 1% or 2% cream applied 2–3 times a day.</li><li>Ketoconazole 2% cream applied 1–2 times a day (for adults aged 18 years and older).</li></ul></li><li><strong>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/\">Prescribing information</a> for detailed information on</strong> intravaginal, oral, and topical antifungals, including information on contraindications and cautions, adverse effects, and drug interactions.</li><li><strong>Be aware that</strong> intravaginal clotrimazole, oral fluconazole, and topical clotrimazole can be purchased over-the-counter.</li></ul></li><li><strong>Advise the woman:</strong><ul><li>To return if symptoms have not resolved within 7–14 days. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#managing-treatment-failure\">managing treatment failure</a> for more management information.</li><li>On measures to aid symptom relief and prevent recurrence. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#general-advice-on-self-management\">self-management advice</a> for more information.</li></ul></li><li><strong>Follow-up and test of cure are <em>not</em> necessary if symptoms resolve.</strong></li><li><strong>Do not routinely treat </strong><strong>an asymptomatic sexual partner.</strong><ul><li>If the male partner of a woman with vulvovaginal candidiasis has balanitis (characterized by erythematous areas on the glans of the penis, pruritus, and/or irritation), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/balanitis/\">Balanitis</a> for management information.</li></ul></li></ul><!-- end field 55741aef-3737-46d0-9633-372454882100 --><!-- end item 0625f8ee-7270-4d6d-87aa-3d2657f18f82 -->","subChapters":[{"id":"298d1076-5efc-504b-b644-d9c886d60418","slug":"initial-courses-of-antifungals","fullItemName":"Initial courses of antifungals","depth":4,"htmlHeader":"<!-- begin field f8dcf595-ef0c-4120-bb55-a6c400d88964 --><h4>What initial courses of antifungals are recommended for women with uncomplicated vulvovaginal candidiasis?  </h4><!-- end field f8dcf595-ef0c-4120-bb55-a6c400d88964 -->","summary":null,"htmlStringContent":"<!-- begin item aa602309-cf12-4085-b2da-a6c400d887a0 --><!-- begin field 22169feb-f8a1-4302-874b-a6c400d88964 --><ul><li><strong>For intravaginal creams, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a></strong><strong><em>,</em> the recommended initial treatments and doses are:</strong><ul><li>Clotrimazole 10% cream — insert 5 g into the vagina as a single dose at night.</li><li>Fenticonazole 2% cream <strong>—</strong> insert 5 g into the vagina in the morning and evening for 3 days.</li></ul></li><li><strong>For intravaginal pessaries, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a><em>, </em>the recommended initial treatments and doses are:</strong><ul><li>Clotrimazole 200 mg pessaries (3 pessaries) — insert 1 pessary into the vagina once at night for 3 nights.</li><li>Clotrimazole 500 mg single-dose pessary — insert 1 pessary into the vagina once at night as a single dose.</li><li>Econazole nitrate 150 mg single-dose pessary (for adults and children aged over 16 years) — insert 1 pessary into the vagina once at night as a single dose.</li><li>Econazole nitrate 150 mg pessaries (3 pessaries) — insert 1 pessary into the vagina once at night for 3 nights.</li><li>Miconazole nitrate 1.2 g single-dose vaginal capsules (for adults aged 18 years and older) — insert 1 capsule into the vagina once at night as a single dose.</li><li>Fenticonazole 200 mg vaginal capsules (3 capsules) — insert 1 capsule into the vagina once at night for 3 nights.</li><li>Fenticonazole 600 mg single-dose vaginal capsules — insert 1 pessary into the vagina once at night as a single dose.</li></ul></li><li><strong>For oral fluconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-fluconazole/#contraindications-cautions\">contraindications</a>, the recommended initial dose is</strong> 150 mg as a single dose.</li><li><strong>For oral itraconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#contraindications-cautions\">contraindications</a>, the recommended initial dose is </strong>200 mg twice a day for 1 day.</li><li>Prescribers should be aware the use of topical anti-fungals may affect the effectiveness of latex contraceptives. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>]</p><!-- end field 22169feb-f8a1-4302-874b-a6c400d88964 --><!-- end item aa602309-cf12-4085-b2da-a6c400d887a0 -->","subChapters":[]},{"id":"b65b3713-6947-526c-82de-427cd1ac69d5","slug":"basis-for-recommendation-487","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1c9e0c61-05a5-4dea-902c-eebd49def620 --><h4>Basis for recommendation</h4><!-- end field 1c9e0c61-05a5-4dea-902c-eebd49def620 -->","summary":null,"htmlStringContent":"<!-- begin item 48719ba4-786e-4894-bfe0-84b969127ead --><!-- begin field 7567fa72-fa2c-439d-a575-e5dc88fe0c2b --><h5>Antifungal treatment</h5><ul><li><strong>Choice of treatment</strong><ul><li>Evidence identified in the British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) suggests that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>]:<ul><li>Intravaginal imidazoles (clotrimazole, miconazole, and butoconazole [not available in the UK]) may reduce symptoms of vulvovaginal candidiasis compared with placebo, and all seem to have similar efficacy to each other.</li><li>Intravaginal imidazoles (clotrimazole, miconazole, and econazole) and oral imidazoles (fluconazole and itraconazole) may be equally effective at achieving clinical cure.</li><li>Oral itraconazole seems to reduce persistent symptoms at 1 week compared with placebo. It is not known whether it is more effective than oral fluconazole.</li></ul></li><li>The British National formulary (BNF) states that both intravaginal and oral imidazole drugs are effective against <em>Candida</em> in short courses of 1–14 days (depending on the preparation used) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Managing women aged 60 years and older</strong><ul><li>This recommendation is based on expert opinion in a review article, which states that after alternative diagnoses have been excluded and risk factors removed (where possible), the investigation and treatment of vulvovaginal candidiasis in older women should be the same as for younger women. However, oral regimens are perhaps more acceptable because of the ease of administration and the avoidance of potentially messy creams and suppositories [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Nwokolo and Boag, 2000</a>].</li></ul></li><li><strong>Managing girls </strong><strong>aged 12–15 years</strong><ul><li>This recommendation is largely based on expert opinion in the BNF for Children and manufacturers’ Summaries of Product Characteristics (SPCs).<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The BNF for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. The option of seeking specialist advice is based on what CKS considers to be good clinical practice.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li><li><strong>Managing breastfeeding women</strong><ul><li>CKS recommends intravaginal clotrimazole or miconazole as there is extensive experience with their use. </li><li>CKS recommends oral fluconazole (if an intravaginal antifungal is unacceptable to the woman) based on the manufacturer's SPC, which states that breastfeeding may be maintained after a single use of a standard dose of 200 mg of fluconazole or less [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>]. Itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Managing vulval symptoms</strong><ul><li>This recommendation is based on the BNF, which states that vaginal applications may be supplemented with a topical antifungal cream for vulvitis and to treat other superficial sites of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li></ul></li></ul><h5>Follow-up and test of cure not necessary</h5><ul><li>In the expert opinion of the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], follow up and test of cure are unnecessary unless symptoms are persistent or recurrent.</li></ul><h5>Advice</h5><ul><li>The recommendation to advise the person to return if symptoms have not resolved within 7–14 days is based on expert opinion in review articles, which states that treatment failure is considered to have occurred if symptoms do not resolve within 7–14 days of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Watson et al, 2002</a>].</li><li>The recommendation to advise on measures to aid symptom relief is based on what CKS considers to be good clinical practice.</li><li><strong>Intravaginal imidazoles (clotrimazole, miconazole, fenticonazole, and econazole) can cause damage to latex contraceptives and can inactivate spermicidal contraceptives.</strong><ul><li>Advise abstinence or the use of non-latex barrier methods during treatment with (and for at least 5 days after stopping) these intravaginal antifungals. </li></ul></li></ul><h5>Not routinely treating an asymptomatic sexual partner</h5><ul><li>In the expert opinion of BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the available data do not support treating asymptomatic male partner of women with vulvovaginal candidiasis.</li><li>However, a small percentage of male partners will develop balanitis, and they should be managed appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul><h5>Treatments not recommended</h5><ul><li><strong>Oral ketoconazole </strong>— due to the increased risk of liver damage associated with its use, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorization for oral ketoconazole. It should no longer be prescribed for the treatment of fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">MHRA, 2013b</a>].</li></ul><!-- end field 7567fa72-fa2c-439d-a575-e5dc88fe0c2b --><!-- end item 48719ba4-786e-4894-bfe0-84b969127ead -->","subChapters":[]}]},{"id":"c323fa94-92e0-5d6f-a7dc-eb14bf950e84","slug":"general-advice-on-self-management","fullItemName":"General advice on self-management","depth":3,"htmlHeader":"<!-- begin field 4a010d6d-c9ef-4e85-9ab9-f58d791270c8 --><h3>What advice on self-management should I give?</h3><!-- end field 4a010d6d-c9ef-4e85-9ab9-f58d791270c8 -->","summary":null,"htmlStringContent":"<!-- begin item 619a0626-b882-417d-b845-e81e6154b7b0 --><!-- begin field be056268-4876-486f-b425-71c2b6593d44 --><ul><li><strong>Advise the woman to:</strong><ul><li>Avoid the following potential predisposing factors:<ul><li>Washing and cleaning the vulval area with soap or shower gels (including those containing perfume and antiseptics [such as tea tree oil]), wipes, and 'feminine hygiene' products.</li><li>Cleaning the vulval area more than once a day.</li><li>Washing underwear in biological washing powder and using fabric conditioners.</li><li>Vaginal douching.</li><li>Wearing tight-fitting and/or non-absorbent clothing.</li></ul></li><li>Wash the vulval area with a soap substitute — this should be used externally and not more than once a day.</li><li>Use a simple emollient to moisturise the vulval area.</li><li>Consider using probiotics (such as live yoghurts) orally or topically to relieve symptoms.  </li></ul></li></ul><!-- end field be056268-4876-486f-b425-71c2b6593d44 --><!-- end item 619a0626-b882-417d-b845-e81e6154b7b0 -->","subChapters":[{"id":"c2c7009b-14a7-58dc-8f48-79484c3fec73","slug":"basis-for-recommendation-c0f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6fe6e3c3-2fe5-4715-9b93-b3c597269df6 --><h4>Basis for recommendation</h4><!-- end field 6fe6e3c3-2fe5-4715-9b93-b3c597269df6 -->","summary":null,"htmlStringContent":"<!-- begin item c0fe1f73-b476-433c-94e7-924e7210f72a --><!-- begin field cf80ca37-b9ea-4295-b2cb-2178c011867d --><h5>Avoiding potential predisposing factors</h5><ul><li>Expert opinion in UK guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight-fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], although the evidence for these is limited, conflicting, or absent.</li><li>Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li></ul><h5>General care of the vaginal skin</h5><ul><li>The advice on the general care of vulval skin and the use of a simple emollient is based on expert advice in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of vulval skin disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCOG, 2011</a>].</li></ul><h5>Probiotics</h5><ul><li>The British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any randomized controlled trials (RCTs) comparing yoghurt containing <em>Lactobacillus acidophilus </em>with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li><li>One small RCT (n = 55) that compared oral <em>L acidophilus </em>with placebo at 1 month when given after a single dose of oral fluconazole (150 mg) found that oral <em>L acidophilus</em>:<ul><li>Decreased vaginal discharge compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 9/26 [35%] with placebo; P = 0.03).</li><li>Reduced the presence of yeast detected by culture compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 10/26 [39%] with placebo; P = 0.01).</li></ul></li><li>There was no evidence of serious harm, but one systematic review (which did not identify any suitable RCTs) stated that oral yoghurt may cause gastrointestinal disturbance in people with lactose intolerance.</li><li>The authors of the BMJ review concluded that the following should be considered:<ul><li>Applying yoghurt intravaginally may be embarrassing and uncomfortable for some women.</li><li>Although different yoghurts can be purchased, their compositions vary, and their effects may differ.</li><li>The effect of alterations in vaginal pH that may occur with intravaginal yoghurt use is unknown.</li></ul></li><li>CKS recommends advising the woman to consider using probiotics because although there is no evidence that they are effective, there is no evidence of (or concerns about) serious adverse effects.</li></ul><h5>Tea tree oil</h5><ul><li>The BMJ Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any RCTs comparing intravaginal tea tree oil with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One systematic review (which did not identify any suitable RCTs) stated that topical tea tree oil can cause skin irritation and a severe allergic rash.</li><li>One case report found that topical tea tree oil was associated with systemic hypersensitivity reaction.</li></ul></li><li>Expert opinion in the joint Faculty of Sexual and Reproductive Healthcare (FSRH) and the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>] and the joint Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group and BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>].</li></ul><!-- end field cf80ca37-b9ea-4295-b2cb-2178c011867d --><!-- end item c0fe1f73-b476-433c-94e7-924e7210f72a -->","subChapters":[]}]},{"id":"449da965-2478-5fb7-b98d-ccfc1b030225","slug":"managing-treatment-failure","fullItemName":"Managing treatment failure","depth":3,"htmlHeader":"<!-- begin field 96362ca9-b94f-47d5-8e47-8d2e8fb5c77d --><h3>How should I manage treatment failure following treatment for uncomplicated vulvovaginal candidiasis?</h3><!-- end field 96362ca9-b94f-47d5-8e47-8d2e8fb5c77d -->","summary":null,"htmlStringContent":"<!-- begin item fdcf1b67-d0a1-4e2a-9e9a-e717855c1b72 --><!-- begin field bd1a26ae-80b6-4ecb-9992-63a70c4dee21 --><ul><li><strong>If symptoms have not resolved within 7–14 days of initial treatment:</strong><ul><li><strong>Confirm that the <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#initial-courses-of-antifungals\">initial treatment</a> was used as recommended.</strong><ul><li>Be aware that topical treatments can cause vulvovaginal irritation, which may be mistaken for treatment failure. </li></ul></li><li><strong>Reassess for <strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/risk-factors/\">risk factors</a></strong></strong><strong> </strong>and remove or control as far as possible.</li><li><strong>Consider </strong><strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">alternative diagnoses</a></strong></strong><strong><em>. </em></strong>If appropriate:<ul><li>Send a vaginal specimen for microscopy, culture, and sensitivity. This may identify a moderate/heavy growth of <em>Candida albicans</em>, non-albicans <em>Candida </em>species, or a mixed infection.</li><li>Consider measuring vaginal pH (if possible) to assess the likelihood of symptoms being due to <em>Candida </em>(pH less than or equal to 4.5), bacterial vaginosis (pH above 4.5), or <em>Trichomonas vaginalis </em>(pH above 4.5).</li><li>Arrange other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">investigations</a> as clinically indicated.</li></ul></li><li><strong>Treat the infection.</strong><ul><li>If there has been a lack of compliance with the <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#initial-courses-of-antifungals\">initial treatment formulation</a>, prescribe the alternative formulation (for example, prescribe oral treatment if there has been poor compliance with intravaginal treatment). </li><li>If compliance is good and symptoms are improving, consider treating with an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#extended-courses-of-antifungals\">extended course</a> of an oral antifungal (fluconazole or itraconazole) or an intravaginal antifungal (clotrimazole, econazole, or miconazole).</li><li><strong>For breastfeeding women, </strong>consider treating with an <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#extended-courses-of-antifungals\">extended course</a> of intravaginal clotrimazole or miconazole, or seek specialist advice.</li></ul></li><li><strong>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/uncomplicated-infection/#general-advice-on-self-management\">self-management advice</a>.</strong></li><li><strong>Refer or seek specialist advice (using clinical judgement) if:</strong><ul><li>The person is aged 12–15 years.</li><li>There is doubt about the diagnosis.</li><li>Symptoms are not improving and treatment failure is unexplained.</li><li>A non-albicans <em>Candida </em>species is identified.</li><li>Treatment fails again.</li></ul></li></ul></li></ul><!-- end field bd1a26ae-80b6-4ecb-9992-63a70c4dee21 --><!-- end item fdcf1b67-d0a1-4e2a-9e9a-e717855c1b72 -->","subChapters":[{"id":"b0586943-ac32-5290-a13b-596565e4bdb0","slug":"extended-courses-of-antifungals","fullItemName":"Extended courses of antifungals","depth":4,"htmlHeader":"<!-- begin field 2d5c2a7b-2096-42ed-b1de-a6b400cc720e --><h4>What extended courses of antifungals are recommended for managing treatment failure in women with uncomplicated vulvovaginal candidiasis?</h4><!-- end field 2d5c2a7b-2096-42ed-b1de-a6b400cc720e -->","summary":null,"htmlStringContent":"<!-- begin item 296d7848-5502-4323-a82a-a6b400cc7023 --><!-- begin field 069e3da7-2e51-42ab-8042-a6b400cc720e --><ul><li><strong>For intravaginal creams, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a><em>,</em> the recommended extended treatments and doses are:</strong><ul><li>Miconazole 2% cream — insert 5 g into the vagina once daily for 10–14 days, <em>or</em> 5 g into the vagina twice daily for 7 days.</li><li>Econazole 1% cream — insert 5 g into the vagina and apply to vulva at night for at least 14 nights.</li></ul></li><li><strong>For intravaginal pessaries, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/intravaginal-antifungals/#prescribing-issues\">contraindications</a></strong><strong><em>,</em> the recommended extended treatments and doses are:</strong><ul><li>Clotrimazole 100 mg pessaries — insert 1 pessary into the vagina once at night for 12 nights.</li><li>Clotrimazole 200 mg pessaries (3 pessaries) — insert 1 pessary into the vagina once at night for 6 nights.</li><li>Econazole nitrate 150 mg pessaries — insert 1 pessary into the vagina once at night for 6 nights (off-label use).</li></ul></li><li><strong>For oral fluconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-fluconazole/#contraindications-cautions\">contraindications</a>, the recommended extended course is</strong> 100 mg once a day for 7 days.</li><li><strong>For oral itraconazole, provided there are no <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/oral-itraconazole/#contraindications-cautions\">contraindications</a>, the recommended extended course is </strong>200 mg once a day for 7 days.</li></ul><!-- end field 069e3da7-2e51-42ab-8042-a6b400cc720e --><!-- end item 296d7848-5502-4323-a82a-a6b400cc7023 -->","subChapters":[]},{"id":"47a9e111-ee4c-5f9d-9775-1d118a6e286d","slug":"basis-for-recommendation-90a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 82e8403e-1e70-4b53-a39e-6739bd8c9c8c --><h4>Basis for recommendation</h4><!-- end field 82e8403e-1e70-4b53-a39e-6739bd8c9c8c -->","summary":null,"htmlStringContent":"<!-- begin item 90a3a8b8-c50b-4ef3-853e-166b3f3535f2 --><!-- begin field fefeef01-25ce-400a-a5a4-a0599e13fe2b --><p>CKS found no evidence or national guidelines specifically on treatment failure of uncomplicated vulvovaginal candidiasis. These recommendations are largely based on what CKS considers to be good clinical practice.</p><h5>Confirming compliance with initial management </h5><ul><li>Expert opinion in guidelines is that treatment with imidazoles relieves symptoms and results in negative cultures in 80–95% of women with uncomplicated vulvovaginal candidiasis who complete treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS therefore recommends considering compliance with initial management if there is treatment failure.</li><li>Topical antifungals usually cause no systemic adverse effects, although local mild burning or irritation may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering this in women with persisting symptoms.</li></ul><h5>Reassessing for predisposing factors</h5><ul><li>CKS recommends reassessing for predisposing factors, as treatment failure is more likely if there is continued exposure to predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li></ul><h5>Considering alternative diagnoses</h5><ul><li>The symptoms of vulvovaginal candidiasis are non-specific and may occur in women with other conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering alternative diagnoses if there is treatment failure, as misdiagnosis is a common cause for treatment failure.</li><li>The recommendations to send a vaginal specimen for microscopy, culture, and sensitivity and to consider measuring vaginal pH (if possible) are extrapolated from expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Treatment</h5><ul><li><strong>Treating with an extended course of an oral or intravaginal antifungal</strong><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li><li>The recommended intravaginal preparations (clotrimazole, econazole, and miconazole) are licensed for extended use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li><li>Although itraconazole and fluconazole are licensed for short-term use (1 day) for the management of vulvovaginal candidiasis, they can safely be used (and are licensed) for longer durations (7 days or longer) to treat other fungal infections (such as pityriasis versicolor [7 days with itraconazole] and oropharyngeal candidiasis [7–21 days with fluconazole]) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li><li><strong>Managing breastfeeding women</strong><ul><li>The recommendation to consider an extended course of intravaginal clotrimazole or miconazole is based on the fact that there is extensive experience with their use. The option of seeking specialist advice is based on what CKS considers to be good clinical practice.</li><li>The manufacturer advises that breastfeeding is not recommended after high-dose treatment with (or repeated use of) oral fluconazole, except for potentially life-threatening infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>], and itraconazole is not recommended for use in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li></ul><h5>Referral or specialist advice</h5><ul><li>The recommendation to arrange referral or seek specialist advice for girls aged 12–15 years is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The British National Formulary (BNF) for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. CKS recommends referral or seeking specialist advice if this does not work.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li><li>The recommendation to arrange referral or seek specialist advice if non-albicans <em>Candida</em> species is identified is based on expert opinion in guidelines issued by the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which state that:<ul><li>The optimal treatment of non-albicans vulvovaginal candidiasis is currently unknown. Options include longer duration of treatment (7–14 days) with a non-fluconazole azole regimen (oral or topical) as first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>In some people with resistant organisms, treatments that should only be initiated by a specialist, or are difficult to obtain in primary care, may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li><li>The other recommendations on when to arrange referral or seek specialist advice are based on what CKS considers to be good clinical practice.</li></ul><!-- end field fefeef01-25ce-400a-a5a4-a0599e13fe2b --><!-- end item 90a3a8b8-c50b-4ef3-853e-166b3f3535f2 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}